{
    "nctId": "NCT04850625",
    "briefTitle": "Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine",
    "officialTitle": "Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 224,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive.\n* Patients were previously treated with trastuzumab in the advanced setting and a taxane in any setting.\n* Patients received lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2) or pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days) for at least one cycle, starting from Jun 2015 to Jan 2021.\n* Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions.\n\nExclusion Criteria:\n\n* Incomplete medical history",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}